Edition:
United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

1.69USD
2:34pm EST
Change (% chg)

$0.22 (+14.97%)
Prev Close
$1.47
Open
$1.54
Day's High
$1.73
Day's Low
$1.48
Volume
215,953
Avg. Vol
53,208
52-wk High
$3.05
52-wk Low
$0.49

GALT.OQ

Chart for GALT.OQ

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 2.31
Market Cap(Mil.): $43.21
Shares Outstanding(Mil.): 29.40
Dividend: --
Yield (%): --

Financials

  GALT.OQ Industry Sector
P/E (TTM): -- 47.00 29.32
EPS (TTM): -0.83 -- --
ROI: -135.26 -4.07 13.03
ROE: -293.75 4.71 14.17

BRIEF-Galectin Therapeutics has says can cover expenditures through 2017 - SEC filing

* Has generated sufficient financing to cover currently planned expenditures through 2017 - sec filing

Feb 01 2017

BRIEF-Richard Uihlein reports 7.89 pct stake in Galectin Therapeutics

* Richard Uihlein reports 7.89 percent stake in Galectin Therapeutics Inc as of Dec 22 - SEC filing Source text: (http://bit.ly/2jMCBRA) Further company coverage:

Jan 18 2017

BRIEF-Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data

* Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data, seeking strategic partnerships for therapy of severe skin diseases Source text for Eikon: Further company coverage:

Nov 10 2016

BRIEF-Galectin Therapeutics Q3 loss per share $0.19

* Galectin Therapeutics Inc- on track for reporting of top-line results in december of 2017 for nash-cx trial

Nov 08 2016

BRIEF-Galectin says announces top-line data from exploratory phase 2A pilot trial (NASH-FX)

* Galectin therapeutics announces top-line data from exploratory phase 2a pilot trial (nash-fx) with gr-md-02 in nash patients with advanced fibrosis

Sep 27 2016

BRIEF-Galectin Therapeutics posts results from extended psoriasis clinical trial - SEC Filing

* Says announces results from 12-week extension of phase 2A psoriasis clinical trial - SEC Filing

Aug 25 2016

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF77.40 +0.70
Merck & Co., Inc. (MRK.N) $65.39 -0.00
Roche Holding Ltd. (ROG.S) CHF246.50 +2.50
Roche Holding Ltd. (RO.S) CHF249.60 +1.80
Eli Lilly and Co (LLY.N) $80.34 -0.05
Momenta Pharmaceuticals, Inc. (MNTA.OQ) $15.77 -3.22

Earnings vs. Estimates